Trial Profile
Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Apr 2019 Results published in the Hepatology Research
- 25 Mar 2019 Status changed from recruiting to completed.
- 27 Mar 2017 New trial record